文献速递胰腺与胆道疾病消化内镜

一项前瞻性队列研究评估PAN-PROMISE患者报告结局指标检测ERCP术后并发症

A Prospective Cohort Study Evaluating PAN-PROMISE, a Patient-reported Outcome Measure to Detect Post-ERCP Morbidity.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-09-06

该前瞻性队列研究在2个学术中心纳入679例ERCP患者,用PAN-PROMISE量表在基线、术后48-72小时、7天和30天评估。32例(4.7%)发生PEP,147例(21.6%)PAN-PROMISE评分升高,其中仅20例(13.4%)符合CC标准的PEP(不一致性P<.001)。结论认为大量患者ERCP后虽有明显症状负担但未发生PEP,需进一步研究。

要点

  • PAN-PROMISE评分7天升高>7分定义为高并发症负担,发生率21.6%。
  • PEP发生率4.7%,与PAN-PROMISE升高不一致(P<.001)。
  • 胰腺癌和原发性硬化性胆管炎患者PAN-PROMISE升高的比值比最高。

核心结论

  • 大量患者ERCP后经历显著并发症负担,但并未发生PEP或其他不良事件。
  • 未来需要进一步研究以更好地描述症状增加的原因及减少ERCP后症状负担的潜在干预措施。

研究设计与样本

  • 前瞻性队列研究,2021年9月至2022年8月在2个学术中心纳入679例接受ERCP的患者。
  • 在基线、ERCP后48-72小时、7天和30天施测PAN-PROMISE并评估生活质量和工作效率。
  • PEP由3名医师委员会依据Cotton共识标准定义。
  • ERCP后高并发症负担(PROM升高)定义为术后7天PAN-PROMISE评分增加>7分。
  • 采用McNemar检验评估PEP与PROM升高之间的不一致性。

主要发现

  • 共纳入679例患者,ERCP主要适应证为胆总管结石(30%)和恶性胆道梗阻(29%)。
  • 32例(4.7%)发生PEP;147例(21.6%)PROM升高,其中仅20例(13.4%)符合CC标准的PEP(不一致性P<.001)。
  • PROM升高与较低的身体生活质量及直接和间接医疗费用增加强烈相关(PAN-PROMISE每增加1分,费用分别增加80美元和25美元)。
  • 胰腺癌患者(比值比4.52;95%置信区间1.68-10.74)和原发性硬化性胆管炎患者(比值比1.79;95%置信区间1.29-2.45)PROM升高的比值比最高。

关键数值与推荐

  • PEP定义采用Cotton共识标准,由3名医师委员会判定。
  • PROM升高定义为ERCP后7天PAN-PROMISE评分增加>7分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来需要进一步研究以更好地描述症状增加的原因及减少ERCP后症状负担的潜在干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The Cotton Consensus (CC) criteria for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) may not capture post-ERCP morbidity. PAN-PROMISE, a patient-reported outcome measure (PROM), was developed to quantify acute pancreatitis-related morbidity. This study aims to determine the value of PAN-PROMISE in independently defining ERCP-related morbidity. METHODS: We conducted a prospective cohort study of patients undergoing ERCP at 2 academic centers from September 2021 to August 2022. We administered PAN-PROMISE and assessed quality of life and work productivity at baseline, 48 to 72 hours, 7 days, and 30 days following ERCP. PEP was defined by a 3-physician committee using the CC criteria. We defined high morbidity following ERCP (elevated PROM) by an increase of PAN-PROMISE score of >7 at 7 days post-procedure. The McNemar test assessed discordance between PEP and elevated-PROM. RESULTS: A total of 679 patients were enrolled. Choledocholithiasis (30%) and malignant biliary obstruction (29%) were the main indications for ERCP. Thirty-two patients (4.7%) developed PEP. One hundred forty-seven patients (21.6%) had an elevated PROM, whereas only 20 of them (13.4%) had PEP by the CC criteria (P < .001 for discordance). An elevated PROM strongly correlated with lower physical quality of life and increased direct and indirect health care costs ($80 and $25 per point increase in PAN-PROMISE, respectively). Patients with pancreatic cancer (odds ratio, 4.52; 95% confidence interval, 1.68-10.74) and primary sclerosing cholangitis (odds ratio, 1.79; 95% confidence interval, 1.29-2.45) had the highest odds of elevated PROM. CONCLUSIONS: A substantial number of patients experience significant morbidity after ERCP despite not developing PEP or other adverse events. Future studies are needed to characterize better the reasons behind this increase in symptoms and potential interventions to reduce the symptom burden post-ERCP. CLINICALTRIALS: gov number, NCT05310409.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Thiruvengadam NR, Kouanda A, Kalluri A, et al. A Prospective Cohort Study Evaluating PAN-PROMISE, a Patient-reported Outcome Measure to Detect Post-ERCP Morbidity. Clin Gastroenterol Hepatol. 2022. PMID: 36075501. doi:10.1016/j.cgh.2022.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。